Business Context and Reporting Period
This Form 8-K was filed by Pavmed Inc. on March 13, 2023, reporting events that occurred on March 7, 2023. The filing primarily concerns a material definitive agreement entered into by Lucid Diagnostics Inc., which is identified within the text as the "Company" for the purpose of the transaction described.
Key Financial Metrics
The filing details a private placement financing event rather than standard operating financial results.
- Transaction Type: Private placement of Series A Convertible Preferred Stock.
- Shares Issued: 13,625 shares.
- Purchase Price: $1,000 per share.
- Aggregate Gross Proceeds: $13.625 million.
- Closing Date: March 7, 2023.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels for Pavmed Inc. or Lucid Diagnostics Inc. at this time.
Material Changes
The primary material change is the entry into subscription agreements for the sale of newly designated Series A Convertible Preferred Stock. This transaction resulted in a capital raise of $13.625 million for Lucid Diagnostics Inc. Additionally, a Certificate of Designation for the Series A Preferred Stock was filed with the Delaware Secretary of State, constituting a material modification to the rights of security holders.
Guidance, Outlook, and Risks
The filing does not contain specific management commentary, forward-looking guidance, or a discussion of risks and contingencies regarding future operations. It references a separate Current Report on Form 8-K filed by Lucid Diagnostics on March 13, 2023, for a more detailed description of the offering and ancillary agreements.
Investor Verification Checklist
- Verify the corporate relationship between Pavmed Inc. (the registrant) and Lucid Diagnostics Inc. (the entity receiving the funds), as the filing implies a significant operational link or acquisition context.
- Review the referenced "Preferred Offering 8-K" filed by Lucid Diagnostics on March 13, 2023, for full details on the rights, preferences, and limitations of the Series A Preferred Stock.
- Confirm the impact of the $13.625 million capital raise on the consolidated balance sheet and liquidity position of Pavmed Inc.
- Examine the Registration Rights Agreement (Exhibit 10.1) to understand future liquidity options for the new preferred shareholders.